It has signed a 5-year R&D partnership with Harvard University to develop novel biologics, vaccines, cell and gene therapies, and other complex medicines. A $30 million investment from Resilience will fund faculty research, coordinated by the university’s office of technology development, into therapeutic and manufacturing technologies with an eye toward clinical development and commercialization. The partners claim to have identified one technology to culture millions of in vitro cells that behave like skeletal muscle stem cells for the treatment of skeletal muscle disorders. Resilience has formed a company, Circle Therapeutics, to license the technology, which was developed in the lab of Lee Rubin, a professor of stem cell and regenerative biology at Harvard.
by Rick Mullin |
October 20, 2021